
To determine whether changes in objective response measures proposed by the National Institutes of Health correlate with clinical benefit, such as symptom burden, quality of life, and survival zzso we analyzed data from a zzso prospective cohort of 283 patients with chronic zzso disease requiring systemic zzso The median follow-up time of survivors was zzso months zzso zzso zzso after zzso zzso measures included the Lee symptom scale and zzso zzso zzso zzso measures included the Short zzso zzso Assessment of Cancer zzso zzso zzso and Human zzso zzso zzso and zzso responses were calculated by comparing manifestations at the zzso visit and those at the enrollment visit using a provisional zzso Complete or partial responses were considered zzso and stable or progressive disease was considered zzso zzso zzso response rate at 6 months was zzso zzso response rates were zzso for skin, zzso for eyes, zzso for mouth, and 51% for gastrointestinal zzso Response at 6 months, as calculated according to the provisional response algorithm, was correlated with changes in symptom burden in patients with newly diagnosed chronic zzso disease, but not with changes in quality of life or survival zzso zzso of the zzso or validation of other more meaningful clinical zzso is warranted for future clinical trials of treatment for chronic zzso zzso 

